DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of “Moderate Buy” from Analysts

DexCom, Inc. (NASDAQ:DXCM) has received a consensus rating of “Moderate Buy” from the eighteen ratings firms that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $98.00.

DXCM has been the subject of a number of research analyst reports. Sanford C. Bernstein raised their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Citigroup increased their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Canaccord Genuity Group increased their price target on DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, Oppenheimer cut their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th.

DexCom Stock Performance

Shares of DXCM opened at $77.19 on Friday. DexCom has a 12 month low of $62.34 and a 12 month high of $142.00. The stock has a fifty day moving average price of $73.58 and a 200-day moving average price of $84.99. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The firm has a market cap of $30.15 billion, a PE ratio of 46.22, a P/E/G ratio of 2.46 and a beta of 1.12.

Insiders Place Their Bets

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Several institutional investors have recently made changes to their positions in DXCM. B. Riley Wealth Advisors Inc. raised its position in DexCom by 42.3% in the third quarter. B. Riley Wealth Advisors Inc. now owns 5,590 shares of the medical device company’s stock valued at $370,000 after purchasing an additional 1,662 shares during the period. Tidal Investments LLC raised its position in DexCom by 68.0% in the third quarter. Tidal Investments LLC now owns 36,742 shares of the medical device company’s stock valued at $2,463,000 after purchasing an additional 14,872 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in DexCom in the third quarter valued at approximately $381,000. World Investment Advisors LLC purchased a new stake in DexCom in the third quarter valued at approximately $2,351,000. Finally, Sanctuary Advisors LLC raised its position in DexCom by 32.2% in the third quarter. Sanctuary Advisors LLC now owns 14,835 shares of the medical device company’s stock valued at $1,080,000 after purchasing an additional 3,615 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.